Product Data Sheet

Cas No.:	2070009-72-0	Cat. No:	PL07270
Product Name:	MMAE-d8		
Product synonym:	-		
Chemical name:	MMAE-d8		
MF:	C39H67N5O7	FW:	726.0279
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	O(C([H])([H])[H])[C@]([H])([C@]([H])(C(N([H])[C@]([H])(C([H])([H])[H])[C@]([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])O[H])=O)C([H])([H])[H])[C@]1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1C(C([H])([H])[C@]([H])([C@]([H])([C@@]([H])(C([H])([H])[H])[H])C([H])([H])C([H])([H])[H])N(C([H])([H])[H])C([C@]([2H])(C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])N([H])C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([H])([H])[H])=O)=O)OC([H])([H])[H])=O		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

MMAE-d_8 是氘代标记的 MMAE。MMAE 是一种 tubulin 抑制剂，抑制有丝分裂。

生物活性	MMAE-d 8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
IC50 & Target[1][2]	Auristatin

体外研究(In Vitro)	Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs are generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. LC-MS is used to measure the concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume is not different among treatment groups 3 days after dose, the intratumoral MMAE measurement reveals two patterns. First, intratumoral MMAE concentration increases proportionally to the ADC dose, which correspondes to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from
体内研究(In Vivo)	Intratumoral MMAE concentrations consistently correlates with the extent of tumor growth inhibition in tumor xenograft models. IHC analysis reveals that nonbinding control-treated tumors consist of both CD30 and CD30cells, presumably because they do not kill either CD30 or CD30 Karpas 299 cells. Only CD30 cells are found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminates most CD30 cells. Interestingly, the two tumors that relapses from cAC10-vcMMAE treatment are also found to be CD30 by the end of study, indicating a small fraction of CD30 cells might have escaped from bystander killing in these two remaining tumors. has not independently confirmed the accuracy of these methods. They are for reference only.
包装储存	Powder -20°C 3 years； 4°C 2 years
溶解度数据	In Vitro: DMSO : 100 mg/mL (137.74 mM; Need ultrasonic)配制储备液